Why You Should Let GlaxoSmithKline plc Look After Your Money

GlaxoSmithKline plc (LON:GSK) is once again fighting the good fight, and shareholders are set to benefit. Find out how.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline

Right off the bat, you must know that it’s very difficult to go wrong with healthcare stocks, generally speaking. I’m not talking about start-up companies, or risky plays, I’m talking about well-established, reputable, large medical businesses. One such company is GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

In the middle of last year, Chinese authorities announced that in recent years GlaxoSmithKline used hundreds of travel agencies and consulting firms to funnel nearly three billion yuan in kickbacks to GSK managers, doctors, hospitals and others who prescribed their drugs. Did GlaxoSmithKline really think it could get away with this? Who knows… the company did, though, raise the white flag and four executives have since been arrested. That’s hurt GlaxoSmithKline’s reputation. The good news is that the company is making amends, and it’s certainly not alone in receiving a slap on the wrist by the authorities. Many of the UK’s banks have also been called into the Head Teacher’s office in recent years. You’d be hard-pressed to find any squeaky clean multinational corporation.

Even better, GlaxoSmithKline — whether it’s because it’s trying to make amends from its recent indiscretions or not — is now very much on the ‘PR front foot’, for want of a better term. As recently as last week, the pharmaceuticals company announced it was helping to lead the charge against the outbreak of the Ebola virus in West Africa.

This plays to two key elements of the company:

Firstly, the company does appear to have a social conscience. That’s crucial for its image — which is vital when it comes to healthcare companies. GlaxoSmithKline, too, is making obvious attempts to crack health problems in emerging countries. This all speaks well of the management culture (notwithstanding GlaxoSmithKline’s recent controversies).

Second, GlaxoSmithKline’s research and development budget is massive — we’re talking billions of dollars’ worth. Why is this important? Well, think of a pharmaceutical company’s R&D like a mining company’s exploration activities. It’s how these companies grow and evolve.

There will only be more and more demand for pharmaceutical products as the world’s population ages. There is also an emerging and growing gap between the world’s rich and poor. GlaxoSmithKline is well-positioned to lead the fight against the health dilemmas that will emerge from both of these issues.

And from a share market strategy viewpoint, healthcare companies the world over have been outperforming in recent years. For instance, if you had been overweight healthcare and consumer staples stocks in the past few years, there’s every chance your portfolio would be fatter than it was to start with.

The technical aspect of this stock speaks for itself. For the past five years, GlaxoSmithKline has been in a nice 45-degree up-trend. It was hit hard earlier this year as news emerged that it was facing criminal investigation for its misconduct (on more than one continent). The shares, though, have since rebounded. The healthcare giant has insisted it’s cutting the cancer out, and indeed says the disease of corruption is ”not systemic”. Maybe that’s why its shares are recovering.

The bottom line is that if the company can successfully clean up its act, it’s a stock market winner. The smart money says it will clean up its act, while recent evidence proves it’s at least back fighting the good fight.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

David Taylor has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »